期刊
PEDIATRIC BLOOD & CANCER
卷 -, 期 -, 页码 -出版社
WILEY
DOI: 10.1002/pbc.30166
关键词
ALL; BMT; hematology; oncology
Hematological toxicity is a common adverse effect following CD19-CAR T-cell therapy. A case study presents the successful use of CD34(+) hematopoietic stem cell boost in treating hematotoxicity.
Hematological toxicity (hematotoxicity) leading to peripheral cytopenias is a common long-term adverse effect following the use of CD19-chimeric antigen receptor (CD19-CAR) T-cell therapies. However, management remains unclear for patients whose cytopenias persist beyond 1 month after CAR T-cell infusion. We present the case of a 21-year old who received CD19-CAR T-cell therapy for relapse following a haploidentical transplant. He developed hematotoxicity and consequently multiple life-threatening infections. We administered a CD34(+) hematopoietic stem cell boost (HSCB) from his transplant donor, which led to hematopoietic recovery and resolution of his infections without any effect on the activity of CD19-CAR T cells. CD34(+) HSCB can be a safe and effective option to treat hematotoxicity following CD19-CAR T-cell therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据